COVID-19, Cytokine Storm, Dialysis; Complications
Conditions
Keywords
dialysis, cytokine, COVID-19
Brief summary
Patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD), are at high risk of a severe form of COVID-19. This study aims to characterize the inflammatory and antiviral response during SarsCov2 infection in adult
Detailed description
Inclusion criteria were (1) Adult (\>18 years old) patient on HD \> 6 months, and (2) infection by SARS-CoV-2. Diagnosis of COVID-19 was assessed by Reverse-Transcriptase-Polymerase Chain Reaction (RT-PCR) for SARS-CoV-2 in nasopharyngeal swab or by typical COVID-19 radiological images on thoracic computerized tomography (CT scan). Severe forms of COVID-19 were defined as requiring oxygen therapy, admission in intensive care unit (ICU) or death Primary end point : \* Characterization the cytokine's profile at the early (day 7) and inflammatory (day 14) phase of COViD-19 in HD patient Secondary End points : * Analyse the kinetic of the antiviral response (type I and III interferon ) between the early (day 7) and inflammatory (day 14) phase of COViD-19. * Analyse the kinetic of proinflammatory cytokine response between the early (day 7) and inflammatory (day 14) phase of COViD-19. * Define an antiviral signature associated with severe form of COVID-19 * Define an anti inflammatory signature associated with severe form of COVID-19 Cytokine's profile is define by the measure of 28 cytokines by Luminex technology
Interventions
None listed
Sponsors
AURA Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult (\>18 years old) patient on HD \> 6 months, and * Infection by SARS-CoV-2. Diagnosis of COVID-19 was assessed by Reverse-Transcriptase-Polymerase Chain Reaction (RT-PCR) for SARS-CoV-2 in nasopharyngeal swab or by typical COVID-19 radiological images on thoracic computerized tomography (CT scan). The date of diagnosis was defined as the day when RT-PCR or CT-scan confirmed the diagnosis.
Exclusion criteria
* Inability to give consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterization of the cytokine profile during the early phase of COVID-19 | Measurement at Day 7 of COVID-19 | Measurement of 29 cytokines by Luminex including type I and Type III Interferon |
| Characterization of the cytokine profile during the inflammatory phase of COVID-19 | Measurement at Day 14 of COVID-19] | Measurement of 29 cytokines by Luminex including type I and Type III Interferon |
Countries
France
Outcome results
None listed